期刊文献+

两种新突变导致血友病B的分子发病机制研究 被引量:4

Study on the molecular mechanism of two new mutations causing haemophilia B
原文传递
导出
摘要 目的 对所发现的2种FⅨ基因的新突变Cys82Ser和Ile288Ser进行体外研究,以探讨血友病B的分子发病机制.方法 克隆野生型PcDNA3.1(-)FⅨwt表达载体质粒,以此为模板,采用大引物法构建PcDNA3.1(-)FⅨM1(Cys82Ser)、PcDNA3.1(-)FⅨM2(Ile288Ser)突变表达载体质粒.采用脂质体法将这3种表达载体质粒分别瞬时转染人胚胎肾293细胞(HEK293细胞)和中国仓鼠卵巢细胞(CHO细胞),同时以PcDNA3.1(-)空载体质粒为空白对照.经体外培养后获得相应的表达蛋白,所得产物分别采用ELISA法检测蛋白抗原 活性测定检测表达蛋白的FⅨ因子活性 免疫荧光染色法检测蛋白在细胞中的定位情况 RT-PCR法检测各培养细胞的FⅨmRNA水平.结果 2种突变体转染细胞的FⅨmRNA水平与野生型无明显区别.以PcDNA3.1(-)FⅨwt转染细胞裂解液和细胞培养上清液中的FⅨ:Ag为100.0%,细胞培养上清液中的FⅨ:C为100.0%,则PcDNA3.1(-)FⅨM1转染细胞裂解液和细胞培养上清液中的FⅨ:Ag分别为(99.4±4.1)%和(27.1±5.2)%,而细胞培养上清液中的FⅨ:C为(8.5±3.2)% PcDNA3.1(-)FⅨM2转染细胞裂解液和细胞培养上清液中的FⅨ:Ag分别为(31.7±2.5)%和(5.3±1.8)%,细胞培养上清液中的FⅨ:C<1%.细胞免疫荧光试验也证实,转染PcDNA3.1(-)FⅨM1的CHO细胞,其荧光强度与转染PcDNA3.1(-)FⅨwt的CHO细胞相当,转染PcDNA3.1(-)FⅨM2的CHO细胞,其荧光强度明显弱于转染PcDNA3.1(-)FⅨwt的CHO细胞.结论 Cys82Ser突变由于改变了FⅨ的EGF-1区的分子空间构象从而可能导致突变蛋白分泌障碍并存在胞内滞留现象 Ile288Ser突变则可能导致突变蛋白分泌障碍或细胞内降解加速从而引起FⅨ活性降低. Objective To study two new factor Ⅸ mutations Cys82Ser and Ile288Ser in vitro and research the molecular mechanism of haemophilia B. Methods PcDNA3. 1 ( - ) FⅨwt expression plasmid was prepared. The mutated FⅨcDNA expression plasmids, PcDNA3.1 ( - ) FⅨM1 (Cys82Ser) and PcDNA3. 1 ( - ) F Ⅸ M2 (Ile288Ser) were constructed by megaprimer method respectively. Transient expression experiments were performed using HEK293 cells transfected with the expression vectors containing the wild-type or the mutation recombinant cDNA. PcDNA3. 1 ( - ) was used as a blank control. The expression proteins were detected by ELISA, factor activity assay and flourescence stain. Results The results suggested that the two FⅨ gene mutations did not induce the reduction of the mutant FⅨ mRNA compared with the wild-type FⅨ mRNA. The FⅨ:Ag in culture media and cell lysate of wild type conduct were assigned as 100. 0%. The results of PcDNA3.1 ( - ) FⅨ M1 mutation protein were (27. 1 ± 5. 2)% and (99.4 ±4. 1)% respectively. For PcDNA3. 1( - )FⅨM2, the results were (5.3 ± 1.8)% and (31.7 ±2. 5)% respectively. The FⅨ: C in culture media of wild type conduct was also assigned as 100. 0%. Then the two types of mutant protein were ( 8. 5 ± 3.2 ) % and 〈 1%, respectively. Immunofluorescence microscopy result suggested that the intensity of perinuclear spot was reduced in cells transfected with PcDNA3.1 ( - ) FⅨM2 while staining for PcDNA3. 1 ( - ) FⅨM1 was predominantely diffuse without perinnclear enhancement. Conclusions These results strongly suggest that the FⅨ Cys82Ser mutation protein is not been correctly folded, by any possibility. The mutation protein has secretion defect. The secretion dysfunction and the protein degradation intracellular are possiblely the molecular pathology of Ile288Ser mutant protein.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2010年第9期878-883,共6页 Chinese Journal of Laboratory Medicine
关键词 血友病B 因子Ⅸ 突变 Hemophilia B FactorⅨ Mutation
  • 相关文献

参考文献15

  • 1Giannelli F,Green PM,High KA,et al.Haemophilia B:database of point mutations and short additions and deletions-third edition,1992.Nucleic Acids Res,1992,20:2027-2063.
  • 2Haemophilia B mutation database.Version 13[DB/OL].London:King's College,2004[2010-07].http://www.kcl.ac.uk/ip/petergreen/haemBdatabase.html.
  • 3戴菁,刘湘帆,王学锋,傅启华,王文斌,丁秋兰,王鸿利.中国汉族血友病B家系五种新的FⅨ基因突变的研究[J].中华检验医学杂志,2005,28(11):1117-1119. 被引量:10
  • 4莫秋华,徐湘民,钟雄霖,刘忠英.一种改进的大引物PCR定点诱变方法[J].中华医学遗传学杂志,2002,19(1):68-71. 被引量:12
  • 5Yoshitake S,Schach BG,Foster DC,et al.Nucleetide sequence of the gene for human factor Ⅸ (antihemophilic factor B).Biochemistry,1985,24:3736-3750.
  • 6Rao Z,Handford P,Mayhew M,et al.The structure of a Ca (2 +)-binding epidermal growth factor-like domain:its role in protein-protein interactions.Cell,1995,82:131-141.
  • 7Bode W,Brandstetter H,Mather T,et al.Comparative analysis of haemostatic proteinases:structural aspects of thrombin,factor Ⅹa,factor Ⅸa and protein C.Thromb Haemost,1997,78:501-511.
  • 8Celie PH,Lenting PJ,Mertens K.Hydrophobic contact between the two epidermal growth factor-like domains of blood coagulation factor Ⅸ contributes to enzymatic activity.J Biol Chem,2000,275:229-234.
  • 9Zhong D,Bajaj MS,Schmidt AE,et al.The N-terminal Epidermal Growth Factor-like Domain in Factor Ⅸ and Factor Ⅹ Represents an Important Recognition Motif for Binding to Tissue Factor.J Biol Chem,2002,277:3622-3631.
  • 10Watzke HH,Wallmark A,Hamaguchi N,et al.Factor Ⅹ Santo Domingo.Evidence that the severe clinical phenotype arises from a mutation blocking secretion.J Clin Invest,1991,88:1685-1689.

二级参考文献20

  • 1Kammann M,Laufs J,Schell J,et al.Rapid insertional mutagenesis of DNA by polymerase chain reaction(PCR). Nucleic AcidsRes,1989,17∶5404.
  • 2Sarkar G, Sommer SS. The "megaprimer" method of site-directedmutagenesis. Biotechniques,1990,8∶404-407.
  • 3Colosimo A,Xu Z,Novelli G,et al. Simple version of "megaprimer" PCR forsite-directed mutagenesis. Biotechniques, 1999, 26∶870-873.
  • 4Ling M, Robinson BH. A one-step polymerase chain reaction site-directed mutagenesismethod for large gene-cssettes with high efficiency,yield,and fidelity. Anal Biochem,1995,230∶167-172.
  • 5Ko TM,Xu X. Molecular study and prenatal diagnosis of alph- and beta-thalassemiasin Chinese.J Formos Med Assoc,1998,97∶5-15.
  • 6蔡仕萍 简悦威 张基增 等.β地中海贫血产前诊断的简易途径[J].中华医学杂志,1988,68:506-508.
  • 7Aiyar A, Xiang Y, Leis J. Site-directed mutagenesis using overlap extension PCR.Methods Mol Biol,1996,57∶177-191.
  • 8Ling MM, Robinson BH. Approaches to DNA mutagenesis∶ an overview. Anal Biochem,1997,254∶157-178.
  • 9Barnes WM.PCR amplification of up to 35-kb DNA with high fidelity and high yieldfrom bacteriophage templates. Proc Natl Acad Sci U S A,1994,91∶2216-2220.
  • 10Cline J,Braman JC,Hogrefe HH. PCR fidelity of Pfu DNA polymerase and otherthermostable DNA polymerase.Nucleic Acids Res, 1996, 24∶3546-3551.

共引文献20

同被引文献51

  • 1颜景斌.人凝血因子IX突变型研究现状[J].遗传,2005,27(5):833-838. 被引量:5
  • 2戴菁,刘湘帆,王学锋,傅启华,王文斌,丁秋兰,王鸿利.中国汉族血友病B家系五种新的FⅨ基因突变的研究[J].中华检验医学杂志,2005,28(11):1117-1119. 被引量:10
  • 3Amy E. Schmidt and S. Paul Bajaj. Structure Function Relation- ships in Factor IX and Factor IX a. Trends Cardinvasc Meal,2003, 13( 1 ) :3945.
  • 4Chen SH, Yoshitake S,Chance PF, et al. An intragenic deletion of the iactor IX gene in a tamily with hemophilia B. J Clin Invest, 1985,76:2161-2164.
  • 5Ljung R,Petrini P,Tengborn L, et al. Haemophilia B mutations in Sweden :a population-based study of mutational heterogeneity. Brit J Haemat. 2001,113 ( 1 ) : 81-86.
  • 6Lin SW,Shen MC. Genetic basis and carrier detection of hemophil-ia B of Chinese origin. Thromb Haemost, 1993,69 (3) :247-252.
  • 7Bottema CD, Ketterling RP, Ii S, et al. Missense mutations and evo- lutionary conservation of amino acids:evidence that many of the a- mino acids in factor IX function as " spacer" elements. Am J Hum Genet, 1991,49(4) :820-838.
  • 8Costa JM, Ernault P, Vidaud D, et al. Fast and efficient mutation detection method using multiplex PCR and cycle sequencing-appli- cation to haemophilia B. Thromb Haemost ,2000,83 (2) :244-247.
  • 9Kolkman JA, Lenting P J, Mertens K. Regions 301-303 and 333-339 in the catalytic domain of blood coagulation factor Ⅸ are factor Ⅵ- Ⅱ-interactive sites involved in stimulation of enzyme activity. Bio- chem J,1999,339 ( Pt 2) :217-221.
  • 10Bajaj SP, Rapaport SI, Maki SL. A rnonoelonal antibody to factor Ⅸ that inhibits the factor Ⅷ :Ca potentiation of factor Ⅹ activation. J Biol Chem, 1985,260 (21) : 11574-11580.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部